News

The AI-enabled, wearable device is the first FDA-approved, drug-free solution for nasal congestion and allergies in children ages 12 and up.

Infant is closely monitored at subsequent well visits and rechecked after 3 months, showed full resolution of the skin lesion over the heel area.

Study results could guide future approaches to optimize service line definitions, according to the study authors.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Take a quick look at everything you may have missed last month, including the latest FDA updates, top stories, and exclusive interviews.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from May 2025.

In this article, we recap a timeline of recent federal agency changes to routine COVID-19 vaccination intended for the pediatric population.

With the new drug application accepted with priority review, the FDA has assigned a date of November 20, 2025, to complete its review for potential approval.

The hyperpolarized contrast agent for oral inhalation can now be used in patients 6 years and older, lowering the approved indication from 12 years of age.

Colleen Sloan, PA-C, RDN, shares some practical tips for providers and caregivers to help keep children hydrated during the summer.

Colleen Sloan, PA-C, RDN, highlights the connection between poor dietary patterns and mental health challenges in children, and offers nutrient-focused solutions.

Federal health agencies have adjusted COVID vaccine guidance, potentially changing eligibility and access for pediatric patients. Experts respond in this article.

Victor Carrion, MD, explains how providers can recognize the signs of accumulated stress in children and support recovery through education and connection.

New phase 3b durability data revealed nirsevimab reduced RSV hospitalizations in infants by 82.7% through 180 days vs no intervention.

The decision makes hydrocortisone oral solution (Khindivi; Eton Pharmaceuticals) the only FDA-approved oral formulation of hydrocortisone.

Review some of the reactions from experts about the recent FDA approval of roflumilast foam 0.3% to treat scalp and body psoriasis in patients aged 12 years or older.

Can you diagnose this patient?

Infants and toddlers with infection history were more likely to have trouble sleeping, while preschool-aged children experienced daytime tiredness.

"These younger individuals are at much higher risk of getting disease and having complications," said Tina Tan, MD, FIDSA, FPIDS, FAAP.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on the May 2025 cover story of Contemporary Pediatrics.

RFK Jr. stated he "couldn't be more pleased" to announce that COVID-19 vaccination among healthy children and pregnant women has been removed from CDC's immunization schedule.

The approved indication now includes children down to 6 weeks of age to protect against invasive meningococcal disease via serogroups A, C, W, and Y.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

A recently published study found sharp increase in the use of nicotine pouches among US high school students, with usage nearly doubling from 2023 to 2024.

Our editor-in-chief Tina Tan, MD, reacts to a new FDA COVID-19 framework that will limit eligibility for seasonal vaccination in pediatrics.

Roflumilast foam 0.3% trial investigator Jennifer Soung, MD, joined us to discuss the importance of this newly FDA-approved topical treatment for patients aged 12 years or older with scalp and body psoriasis.

The once-daily, steroid-free topical is now approved to treat plaque psoriasis of the scalp and body in patients aged 12 years and older.

“These findings provide evidence that social media may be contributing to the development of depressive symptoms,” said Jason M. Nagata, MD, MSc.

Victor Carrion, MD, emphasizes how pediatricians can monitor and support mental health in youth while navigating limited access to specialized care.

The expanded indication follows original approval in August 2018 for use in previously-treated patients 12 years and older.